Tamoxifen and fluoxymesterone versus tamoxifen and danazol in metastatic breast cancer - A randomized study

Sandra M. Swain, Seth M. Steinberg, Caroline Bagley, Marc E Lippman

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A prospective randomized trial of tamoxifen and fluoxymesterone versus tamoxifen and danazol in metastatic breast cancer was conducted from December 1980 to September 1985. Patients were eligible regardless of site of disease, estrogen receptor status, or age. Sixty-two of sixty-three randomized patients were evaluable for response. Overall response for tamoxifen and fluoxymesterone was 11% with 61% stabilization of disease, versus 12% response rate for tamoxifen and danazol with 59% stabilization. Toxicities with tamoxifen and fluoxymesterone were greater with an increase in masculinization. We conclude that the response rates to the combinations of tamoxifen and fluoxymesterone or tamoxifen and danazol reported are equivalent in this study but that the increased toxicity with tamoxifen and fluoxymesterone would make tamoxifen and danazol the treatment of choice if a combination were to be used.

Original languageEnglish
Pages (from-to)51-57
Number of pages7
JournalBreast Cancer Research and Treatment
Volume12
Issue number1
DOIs
StatePublished - Sep 1 1988
Externally publishedYes

Fingerprint

Fluoxymesterone
Danazol
Tamoxifen
Breast Neoplasms
Estrogen Receptors

Keywords

  • breast cancer
  • danazol
  • fluoxymesterone
  • tamoxifen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Tamoxifen and fluoxymesterone versus tamoxifen and danazol in metastatic breast cancer - A randomized study. / Swain, Sandra M.; Steinberg, Seth M.; Bagley, Caroline; Lippman, Marc E.

In: Breast Cancer Research and Treatment, Vol. 12, No. 1, 01.09.1988, p. 51-57.

Research output: Contribution to journalArticle

Swain, Sandra M. ; Steinberg, Seth M. ; Bagley, Caroline ; Lippman, Marc E. / Tamoxifen and fluoxymesterone versus tamoxifen and danazol in metastatic breast cancer - A randomized study. In: Breast Cancer Research and Treatment. 1988 ; Vol. 12, No. 1. pp. 51-57.
@article{d895f47014e7405bb6cf2f36a2ac787f,
title = "Tamoxifen and fluoxymesterone versus tamoxifen and danazol in metastatic breast cancer - A randomized study",
abstract = "A prospective randomized trial of tamoxifen and fluoxymesterone versus tamoxifen and danazol in metastatic breast cancer was conducted from December 1980 to September 1985. Patients were eligible regardless of site of disease, estrogen receptor status, or age. Sixty-two of sixty-three randomized patients were evaluable for response. Overall response for tamoxifen and fluoxymesterone was 11{\%} with 61{\%} stabilization of disease, versus 12{\%} response rate for tamoxifen and danazol with 59{\%} stabilization. Toxicities with tamoxifen and fluoxymesterone were greater with an increase in masculinization. We conclude that the response rates to the combinations of tamoxifen and fluoxymesterone or tamoxifen and danazol reported are equivalent in this study but that the increased toxicity with tamoxifen and fluoxymesterone would make tamoxifen and danazol the treatment of choice if a combination were to be used.",
keywords = "breast cancer, danazol, fluoxymesterone, tamoxifen",
author = "Swain, {Sandra M.} and Steinberg, {Seth M.} and Caroline Bagley and Lippman, {Marc E}",
year = "1988",
month = "9",
day = "1",
doi = "10.1007/BF01805740",
language = "English",
volume = "12",
pages = "51--57",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Tamoxifen and fluoxymesterone versus tamoxifen and danazol in metastatic breast cancer - A randomized study

AU - Swain, Sandra M.

AU - Steinberg, Seth M.

AU - Bagley, Caroline

AU - Lippman, Marc E

PY - 1988/9/1

Y1 - 1988/9/1

N2 - A prospective randomized trial of tamoxifen and fluoxymesterone versus tamoxifen and danazol in metastatic breast cancer was conducted from December 1980 to September 1985. Patients were eligible regardless of site of disease, estrogen receptor status, or age. Sixty-two of sixty-three randomized patients were evaluable for response. Overall response for tamoxifen and fluoxymesterone was 11% with 61% stabilization of disease, versus 12% response rate for tamoxifen and danazol with 59% stabilization. Toxicities with tamoxifen and fluoxymesterone were greater with an increase in masculinization. We conclude that the response rates to the combinations of tamoxifen and fluoxymesterone or tamoxifen and danazol reported are equivalent in this study but that the increased toxicity with tamoxifen and fluoxymesterone would make tamoxifen and danazol the treatment of choice if a combination were to be used.

AB - A prospective randomized trial of tamoxifen and fluoxymesterone versus tamoxifen and danazol in metastatic breast cancer was conducted from December 1980 to September 1985. Patients were eligible regardless of site of disease, estrogen receptor status, or age. Sixty-two of sixty-three randomized patients were evaluable for response. Overall response for tamoxifen and fluoxymesterone was 11% with 61% stabilization of disease, versus 12% response rate for tamoxifen and danazol with 59% stabilization. Toxicities with tamoxifen and fluoxymesterone were greater with an increase in masculinization. We conclude that the response rates to the combinations of tamoxifen and fluoxymesterone or tamoxifen and danazol reported are equivalent in this study but that the increased toxicity with tamoxifen and fluoxymesterone would make tamoxifen and danazol the treatment of choice if a combination were to be used.

KW - breast cancer

KW - danazol

KW - fluoxymesterone

KW - tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=0023677061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023677061&partnerID=8YFLogxK

U2 - 10.1007/BF01805740

DO - 10.1007/BF01805740

M3 - Article

VL - 12

SP - 51

EP - 57

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -